Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lifting the innate immune barriers to antitumor immunity
Carla V. Rothlin, Sourav Ghosh
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000695-e000695
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Combination strategies to maximize the benefits of cancer immunotherapy
Shaoming Zhu, Tian Zhang, Lei Zheng, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 433
Signal pathways of melanoma and targeted therapy
Weinan Guo, Huina Wang, Chunying Li
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 225
Natural killer cells: a promising immunotherapy for cancer
Junfeng Chu, Fengcai Gao, Meimei Yan, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 112
Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer
J. Li, Jiao Liu, Zhuan Zhou, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 720
Closed Access | Times Cited: 110
The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions
Guang Lei, Li Zhuang, Boyi Gan
Cancer Cell (2024) Vol. 42, Iss. 4, pp. 513-534
Open Access | Times Cited: 108
Regulating trained immunity with nanomedicine
Mandy M. T. van Leent, Bram Priem, David P. Schrijver, et al.
Nature Reviews Materials (2022) Vol. 7, Iss. 6, pp. 465-481
Open Access | Times Cited: 83
Cold and hot tumors: from molecular mechanisms to targeted therapy
Bo Wu, Bo Zhang, Bowen Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 39
Circulating immunotherapy strategy based on pyroptosis and STING pathway: Mn-loaded paclitaxel prodrug nanoplatform against tumor progression and metastasis
Bingjie Wang, Teng Wang, Tianze Jiang, et al.
Biomaterials (2024) Vol. 306, pp. 122472-122472
Closed Access | Times Cited: 19
A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death
Jonathan Mannion, Valentina Gifford, Benjamin R. Bellenie, et al.
Immunity (2024) Vol. 57, Iss. 7, pp. 1514-1532.e15
Open Access | Times Cited: 16
Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?
Robert W. Lentz, Meryl D. Colton, Siddhartha S. Mitra, et al.
Molecular Cancer Therapeutics (2021) Vol. 20, Iss. 6, pp. 961-974
Open Access | Times Cited: 91
Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease
Martijn P. T. Ernst, Mike Broeders, Pablo Herrero-Hernandez, et al.
Molecular Therapy — Methods & Clinical Development (2020) Vol. 18, pp. 532-557
Open Access | Times Cited: 80
Tumor Associated Macrophages, as the Dominant Immune Cells, Are an Indispensable Target for Immunologically Cold Tumor—Glioma Therapy?
Ni Tong, Zhenqiang He, Yujie Ma, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 62
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Moran Gvili Perelman, Rafael Y. Brzezinski, Barliz Waissengrin, et al.
Cardio-Oncology (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 11
Biomimetic Diselenide‐Sonosensitizer Nanoplatform for Enhanced Sonodynamic Therapy and In Situ Remodeling Immunosuppressive Microenvironment via Activating Innate and Adaptive Immunotherapy
Yifan Xue, Qingliang Wang, Y. Eugene Chen, et al.
Advanced Healthcare Materials (2025)
Closed Access | Times Cited: 1
CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration
Mingsu Shi, Yun Gu, Kaifeng Jin, et al.
Cancer Immunology Immunotherapy (2021) Vol. 70, Iss. 7, pp. 1831-1840
Open Access | Times Cited: 51
Tissue-specific modifier alleles determine Mertk loss-of-function traits
Yemsratch T. Akalu, María E. Mercau, Marleen Ansems, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 35
Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy
Renhong Huang, Zheng Wang, Jin Hong, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 10
Open Access | Times Cited: 22
Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies
Jiawen Zhang, Sihui Yu, Qiao Peng, et al.
Cancer Biology and Medicine (2024), pp. 1-20
Open Access | Times Cited: 8
Recent Findings on Therapeutic Cancer Vaccines: An Updated Review
Sara Sheikhlary, David Humberto Lopez, Sophia Moghimi, et al.
Biomolecules (2024) Vol. 14, Iss. 4, pp. 503-503
Open Access | Times Cited: 7
IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma
Jennifer Sun, S. Corradini, Feda Azab, et al.
Leukemia (2024)
Open Access | Times Cited: 6
Shp1 in Solid Cancers and Their Therapy
Alessia Varone, Daniela Spano, Daniela Corda
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 47
TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti‐CTLA4 treatment
Huahua Li, Jia Li, Chenyue Zhang, et al.
Cancer Medicine (2020) Vol. 9, Iss. 19, pp. 7151-7160
Open Access | Times Cited: 40
Immunostimulatory Properties of Chemotherapy in Breast Cancer: From Immunogenic Modulation Mechanisms to Clinical Practice
Jinguo Zhang, Shuaikang Pan, Jian Chen, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 23
Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy
Xiuman Zhou, Ling Jiao, Yuzhen Qian, et al.
Biomolecules (2021) Vol. 11, Iss. 5, pp. 706-706
Open Access | Times Cited: 31
Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
Na Li, Jiahong Wang, Xianquan Zhan
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top